Which Startup Valuation Method Gets You the Right Number at the Right Stage

Your Valuation Is Not a Number. It's a Negotiation Starting Point.

I see this every week - founders treating startup valuation like a math problem with a correct answer. They run a DCF. They plug in a revenue multiple, come up with a number, and walk into a pitch meeting like it's settled.

It is not settled. It never was.

As Peter Thiel put it - and this framing gets closer to the truth than any spreadsheet - "The value is never a premium on the past. It's always a discount to the future." That's the actual game. Investors are pricing what you can become, minus the risk that you don't get there.

Every valuation method lives in that space between belief and risk. Understanding which method to use, and when, is what this guide covers. Not in the abstract. With real numbers, real stage benchmarks, and the specific scenarios where each approach gives you the most advantage.

Why "What's My Startup Worth?" Is the Wrong Question

At the pre-seed stage, the most common way valuations get set is by working backward. An investor decides how much they want to own. The founder decides how much they need to raise. The math determines the valuation.

One early-stage investor from Foundry Group put it directly: "At the very earliest stage of any new venture, it's all about hope and not metrics." Peter Pham, co-founder of Science Inc. - the incubator behind Dollar Shave Club and Bird - made the same point from the founder side: valuation is really based on how much money the founders think they need.

Pre-revenue valuations are entirely subjective. The formal methods - Berkus, Scorecard, VC Method - exist to give both sides a framework to anchor a conversation that is otherwise entirely subjective. Think of them as tools that create a shared language, not tools that generate truth.

With that framing in place, each method works differently, fits a different stage, and maps to different real-world numbers right now.

The Valuation Method Stack - Mapped by Stage

Most valuation content presents all methods as equally available to all startups. That is wrong. The method you use is almost entirely dictated by your stage.

Pre-Revenue / Pre-Seed: Berkus Method

The Berkus Method was created by angel investor Dave Berkus to solve one specific problem. Founders with no revenue were coming in with projections, and those projections were almost always wrong. His solution was to ignore the projections entirely.

Instead, the Berkus Method assigns a dollar value to five risk-reducing factors. Each factor gets a value between $0 and $500,000 based on how well the startup has addressed it. The five factors are a sound idea, a prototype, a quality management team, strategic relationships, and early sales or rollout evidence.

Add them up and you get a pre-money valuation. The original cap was $2.5 million. The method has since been updated to allow higher caps based on regional market averages - if the average seed deal in your market is $6 million, each Berkus factor gets up to 20% of that number, or $1.2 million each.

The Berkus Method works best for pre-revenue startups that have something tangible to show - a prototype, a co-founder with a relevant track record, or early customer conversations. It breaks down when you have literally nothing. A raw idea with no proof gets the minimum on every factor, which produces a valuation so low it does not reflect the reality of the market.

Best for: Pre-revenue companies with at least a prototype and some team credibility.
Output range: $500K to $2.5M at standard caps, higher in modified versions tied to regional averages.

Pre-Revenue / Seed: Scorecard Method

The Scorecard Method, developed by angel investor Bill Payne, starts where the Berkus Method leaves off. Instead of assigning fixed dollar values to abstract factors, it compares your startup to funded peers in the same geography and industry, then adjusts a baseline valuation up or down based on weighted criteria.

The weights look like this. The management team carries 25% of the score - the single biggest factor. The size of the opportunity carries 20%. Product or technology carries 18%. Marketing and sales capability carries 15%. The need for additional funding and other factors each carry 10%.

The output is a multiplier. If your startup scores 1.2x the baseline on team quality, and the baseline pre-seed valuation in your region is $4 million, you land at $4.8 million. If your team is weak but your market is massive, you might still hold $4 million or slightly above.

This method is the most commonly used by angel investors evaluating pre-seed deals in regional ecosystems. It requires real comparable data - you need to know what similar deals in your geography actually closed at, which is where databases like Crunchbase, PitchBook, and AngelList become essential inputs.

Best for: Pre-revenue seed deals where comparable transactions exist in the same market.
Output range: Typically $1M to $5M at pre-seed, $3M to $8M at seed.

Pre-Revenue: Risk Factor Summation Method

The Risk Factor Summation Method is a more granular cousin of the Scorecard. It starts with the same baseline - the average pre-money valuation for comparable companies in your region - then adjusts up or down based on 12 distinct risk categories.

Each risk factor is worth a multiple of $250,000. A factor rated very low risk adds $500,000. A factor rated very high risk subtracts $500,000. The 12 factors include management risk, stage of the business, legislation/political risk, manufacturing risk, sales and marketing risk, funding/capital raising risk, competition risk, technology risk, litigation risk, international risk, reputation risk, and exit risk.

The method gives a more complete picture of downside scenarios than either Berkus or Scorecard. That makes it useful for investors who want to run a structured due diligence conversation, not just agree on a number. In practice, few founders drive this method themselves - it's usually investor-led during a diligence process.

Best for: Seed-stage companies where an angel or VC wants to stress-test valuation assumptions.
Output range: Similar to Scorecard - anchored to regional comparables, adjusted by risk profile.

Seed to Series A: Comparable Transactions

Once your startup has some traction - revenue, users, signed pilots - the comparable transactions method becomes the dominant approach. This is the startup equivalent of pulling comps before pricing a house.

You find recent deals involving companies in the same industry, at the same stage, with similar metrics. You identify what multiples those deals applied to whatever metric was most relevant - monthly recurring revenue for SaaS, active users for consumer apps, gross profit for marketplaces. Then you apply those multiples to your own numbers.

The Brex article on startup valuation gives a clean example of how this works in practice. Take a fictional shipping company that was acquired for $24 million with 700,000 users - that's roughly $34 per user. If your shipping startup has 120,000 users, the comparable transaction method puts your value at around $4 million.

For SaaS companies, the relevant multiple is usually applied to annual recurring revenue (ARR). In high-growth industries, revenue multiples in the 5x to 10x range are common. The exact number depends on growth rate, gross margin, and how close comparable companies are to your profile.

Best for: Post-traction companies (any stage) where transaction data exists for similar businesses.
Output range: Depends entirely on the metric and the multiple, but Series A SaaS companies at $1.5M ARR growing 150% annually can command materially different multiples than a company growing at 50%.

Series A+: The VC Method

The VC Method works backward from an exit. The investor estimates what the company could be worth at acquisition or IPO - the terminal value. They then apply their required return multiple to determine what they need to pay today to make that return.

The formula is straightforward. Post-money valuation equals terminal value divided by the anticipated return on investment. Subtract the investment amount to get pre-money valuation.

Say a VC believes your company could be worth $100 million in five years and needs a 20x return. That implies a post-money valuation of $5 million. If they are investing $1 million, your pre-money valuation is $4 million. The VC Method is not really a valuation tool for founders - it's the investor's internal logic that determines how much dilution they need. Knowing it helps you understand why VCs push back on high valuations: their math stops working at your number.

VCs typically apply standard benchmarks rather than case-by-case financial modeling at early stages. That is why early-stage valuations tend to cluster around market norms rather than spreading widely based on each startup's unique financials.

Best for: Series A and beyond, where the business has a credible path to a meaningful exit.
Output range: Entirely dependent on projected terminal value and the investor's target return multiple.

Series B+: Discounted Cash Flow (DCF)

DCF is theoretically the most rigorous valuation method. It projects future cash flows and discounts them to present value using a discount rate that reflects the risk of the investment. For startups, that discount rate is typically between 30% and 60% - far higher than what you'd use for a mature business.

DCF requires reliable financial projections. Early-stage startups don't have reliable financial projections. Most founders' five-year revenue models are speculative at best. Applying a rigorous methodology to unreliable inputs produces precise-sounding nonsense.

This is why DCF is rarely used before Series C or pre-IPO. At that point, the business model is proven, unit economics are measurable, and financial projections have at least some track record to anchor them. Before that, DCF is mostly useful as a sanity check - a way to test whether the valuation implied by your other methods is consistent with what the business would need to look like in five years to justify it.

Best for: Growth-stage companies (Series C+) with proven business models and measurable unit economics.
Output range: Highly variable - dependent on projection quality and discount rate assumptions.

When You Don't Want to Set a Valuation at All: SAFEs and Convertible Notes

Many early-stage founders skip the valuation conversation entirely by using a SAFE (Simple Agreement for Future Equity) or a convertible note. Y Combinator pioneered the SAFE structure. It lets an investor put in money now, with the investment converting into equity at a later round based on a pre-agreed valuation cap and sometimes a discount.

SAFEs are faster and cheaper to execute than priced equity rounds. They defer the valuation conversation until a more sophisticated lead investor sets a market price at the next round. The tradeoff is that founders and early investors both operate with some uncertainty about what the equity will be worth when conversion happens.

At the pre-seed stage, SAFEs have become dominant. In Q2 of one recent year analyzed by Eqvista, SAFEs constituted 80% of invested capital at the pre-seed stage. A reasonable pre-seed SAFE cap runs from $10 million to $15 million, depending on round size - rounds under $1 million typically see $10 million caps, while rounds between $1 million and $2.5 million tend to see caps around $15 million, according to Carta data. AI-focused pre-seed startups have been pushing $15 million to $20 million caps.

Best for: Pre-seed and seed deals where both parties want to move fast and avoid negotiating a precise valuation.
Key consideration: A SAFE defers dilution clarity, not dilution itself. Founders should model what conversion looks like at various scenarios before signing.

What the Benchmark Data Says Right Now

I see this every week - founders walking into meetings without knowing the numbers they'll be compared against. Here is what the current data shows across more than 3,000 startup valuation observations.

Pre-Seed Valuations Have Not Recovered From the ZIRP-Era Correction

The peak of the easy-money era pushed pre-seed median valuations to around $5.88 million. The correction that followed dropped that number to around $3.81 million at the trough. Current data puts pre-seed median valuations around $3.95 million to $4.01 million - a recovery, but still roughly 33% below the peak.

What that means practically: if you raised a pre-seed round at a $7 million or $8 million valuation during the peak period, you are likely dealing with a valuation that the current market does not support. Founders coming to market now face a more grounded environment - which is better for building realistic capital structures that don't create problems at Series A.

PitchBook and NVCA data puts the median pre-seed pre-money valuation at $7.7 million as of Q3 of a recent quarter (down from $8 million the quarter before). Equidam and PitchBook use different methodologies and sample different populations - Equidam skews toward earlier-stage global companies, PitchBook captures more U.S. institutional deals. Both data sets are valid; they're measuring slightly different populations.

Dilution Is Rising Again - And Founders Aren't Tracking It

One of the most underreported dynamics in early-stage fundraising right now is that dilution per round is creeping back up. At the height of the frothy market, average pre-seed dilution dropped to around 14.1% - founders were giving up historically small equity stakes for capital. The post-correction peak hit around 21% dilution.

Current data shows dilution running around 19% to 19.5% at pre-seed, and ticking upward quarter over quarter. That matters because dilution compounds. If you give up 19.5% at pre-seed, 20% at seed, and 20% at Series A, you are looking at owning somewhere around 50% to 60% of what you started with before you reach Series B. Model this early. Optimize the method you use to set your initial valuation. The equity you protect now is the equity you still own at Series B.

Where You Are Changes Your Number More Than You Think

Geography is the variable most founders underweight when thinking about valuation. The regional spread in pre-seed valuations is enormous.

U.S. pre-seed valuations run 63% higher than European ones on average. That makes the Scorecard Method geography-sensitive in a way that matters a lot. The baseline you use has to reflect your actual market. A European founder using U.S. comparables is setting a valuation that local investors won't support, regardless of what the method says.

Gulf-based VC activity has increased significantly in recent years, and Middle East pre-seed valuations have moved above European ones as a result. Oceania has the lowest dilution rate globally at 11.67%, which suggests founders in Australia and New Zealand are retaining more equity per dollar raised than almost anywhere else.

Your Industry Sets the Range More Than Your Stage Does

Industry is the second major variable that shapes what valuation method and what range is realistic for your company.

Fintech startups command the highest pre-seed valuations on average - $9.1 million - which is 73% above the U.S. average. Healthcare and climate startups follow closely. Software and IT companies get lower absolute valuations but give up the least equity, with an average dilution of just 10.6%. That means SaaS founders often retain more ownership percentage even if their dollar valuation is lower.

For any founder using the Scorecard Method or comparable transactions, this table explains why comparing yourself to the wrong industry peer group is such a significant mistake. A SaaS company comparing itself to fintech comps will set a valuation the market won't support. A fintech company using general software comps will undervalue itself.

AI Valuations Are Bifurcating Fast

AI startups command a meaningful valuation premium at the seed stage. The premium runs around 42% at seed and approximately 70% at Series A compared to non-AI peers. A 70% valuation difference at Series A is not a rounding error.

But the premium is narrowing as AI becomes the baseline, not the differentiator. With Y Combinator's recent cohorts featuring 70+ companies building AI agents across 18 different categories, the market is crowding fast. Investors who were willing to apply an AI premium to any company using a large language model are becoming more selective about what qualifies for that premium.

The premium now tracks to defensibility, not to the presence of AI. Companies with proprietary training data, specialized models with demonstrated accuracy advantages, or clear enterprise distribution moats still command the premium. Companies that are primarily wrapping a foundation model in a UI are facing much more pushback on valuation.

What this means for valuation method selection: AI founders at pre-seed can still push the upper end of Berkus and Scorecard ranges if they have genuine IP or distribution advantages. AI founders who are primarily prompt-engineering existing models should use the standard comparable set for their industry vertical, not the AI premium comps.

What VCs Use Versus What They Say They Use

VCs have a finding that almost no valuation content covers directly. The methods VCs say they use and the methods they use in practice are different things.

In formal pitch materials and term sheets, VCs reference Berkus, Scorecard, and VC Method. In actual decision-making, the dominant inputs are two things: what comparable deals in their portfolio have priced at, and how much dilution the founders will accept.

One practitioner who has worked across multiple funded startups described the dynamic this way. After the initial pitch, the investor's internal logic is almost entirely driven by ownership targets. A VC who needs 20% to justify a board seat is going to back into a valuation based on your ask. If you are raising $2 million and they need 20%, you are a $10 million post-money company regardless of what any method says. The formal methods are the justification layer, not the starting point.

This is why Elon Musk's advice on valuation has more practical utility than most textbook frameworks. He said it plainly: "If you have a choice of a lower valuation with someone you really like or a higher valuation with someone you have a question mark about, take the lower valuation." The investor relationship compounds across years. The extra 10% on your cap table at pre-seed is a rounding error compared to having the wrong partner for the next five years.

The strategic implication: use the formal methods to build a defensible range. Use that range to create competing investor interest. Two term sheets do more for your valuation than any model. As one source put it, competition between investors drives valuation - two term sheets beat any valuation formula.

Team Size and Valuation

Data across more than 3,000 startup companies shows a clear pattern that rarely comes up in valuation discussions. Solo founders make up 44.3% of all startups but only receive 20.2% of VC-backed deals. Two-founder teams, at 30.5% of all startups, capture 37.2% of VC investment.

Solo founders represent 41.6% of companies that reach $1 million or more in annual revenue. That is a disproportionately high hit rate given their share of VC funding. The implication is that bootstrapped solo founders outperform their VC-backing rate - and that the solo founder discount applied by VCs at the valuation stage may be overcorrecting for actual risk.

For solo founders, this creates a practical valuation challenge. You will face pushback that a co-founder would resolve. The most direct paths to countering that valuation discount are a strong advisory board with names investors recognize, a demonstrated track record in a relevant domain, or enough traction that the team composition becomes less relevant to the conversation.

Two or three founders get the best of both worlds on VC deals: 37.2% of VC-backed companies have two founders, and the capital capture rate matches or exceeds their overall representation in the startup population.

How to Pick the Right Method for Your Situation

Forget trying to use every method. Use the one that gives you the strongest defensible number given your stage, industry, and what data you have access to.

Here is a stage-gated selector.

No revenue, no prototype yet

You have almost no inputs that any formal method can use. The most honest approach is to anchor on what similar companies in your geography raised at pre-seed, pick a number that allows you to hit 18 months of runway, and present it as the capital-driven ask rather than the output of a valuation model. Consider a SAFE with a cap in the $8M to $12M range rather than trying to negotiate a priced round.

No revenue, prototype exists

Use Berkus. Run the five factors honestly. If your market average is above $2.5 million, apply the modified version that scales each factor to 20% of the regional average. Cross-reference with two or three recent seed deals you can find in your geography on Crunchbase or AngelList.

No revenue, strong team with track record

Use Scorecard. The team factor carries 25% of the weight, which is where your strength shows up most. Start with the regional baseline and apply your multiplier upward on team quality. Document your comparable deals so you can defend the baseline when an investor asks.

Early revenue ($0 to $500K ARR)

Use comparable transactions alongside Scorecard. Find three to five recent deals in your vertical and calculate the implied EV-to-ARR multiple. Your valuation should fall within the range those multiples imply, adjusted up or down based on your growth rate relative to the comparable companies.

Post-traction ($500K to $2M ARR)

Lead with revenue multiples from comparable transactions. Layer in the VC Method to understand what exit math the investor is running. A SaaS company at $1.5 million ARR growing at 150% annually commands a fundamentally different multiple than one growing at 50%, even if the absolute revenue number is the same.

Series A and beyond

Revenue multiples dominate. DCF becomes a sanity check. The VC Method is the investor's internal logic - knowing it helps you understand the math behind the offer you receive. Focus on demonstrating the unit economics (LTV, CAC, gross margin) that make the revenue multiple defensible.

The Overvaluation Trap - And How to Avoid It

Every founder wants the highest valuation. But chasing the highest number creates a specific set of problems that play out in the next round.

If you raise at too high a valuation early, you are setting the floor for your next round. Investors at Series A price relative to what you raised at seed. If your traction between rounds didn't grow into the implied value, the most likely outcome is a flat round - raising at the same valuation - or a down round, which means your valuation drops. Down rounds are not just financial events. They signal to the market that something went wrong, which affects future fundraising even after you've fixed the underlying problem.

The overvaluation risk compounds further when terms are loaded in ways that compensate investors for a high price. A slightly lower valuation with straightforward terms is often the better deal than a high valuation with aggressive liquidation preferences, anti-dilution provisions, or protective clauses that will constrain your future fundraising and exit options.

A slightly lower valuation with clean, founder-friendly terms may be a better deal overall than a high valuation loaded with aggressive investor protections. This is a consideration that rarely shows up in the formal valuation methods but shapes the actual economics of every funding round.

Using Lead Generation to Support Your Valuation Story

One thing founders consistently underestimate is how much early traction data changes the valuation conversation. Companies with over 1,000 early adopters or partnerships with industry leaders often attract higher valuations at pre-seed and seed - not because the revenue exists yet, but because the demand signal is measurable.

Building that demand signal before you raise is one of the highest-ROI activities a pre-seed founder can do. Waitlists, paid pilots, letters of intent from potential customers - all of these inputs shift your Berkus and Scorecard scores upward, and your Berkus and Scorecard scores move with them, expanding the range you can defensibly claim.

For B2B founders, the most direct path to building that demand signal fast is targeted outreach to potential customers before the round closes. Tools like ScraperCity let you search millions of contacts by title, industry, location, and company size - so you can find the exact decision-makers who would be your first customers, reach them before the pitch, and walk into investor meetings with real demand data instead of projected TAM slides.

Stage-by-Stage Dilution Model - What You're Signing Up For

Most founders think about each round in isolation. What they should be thinking about is how dilution compounds across rounds. Here is a simple model using current market benchmarks.

Start with 100% ownership at founding.

Pre-seed round: Give up 15% to 19.5%. You own roughly 80% to 85%.

Seed round: Give up another 20%. You own roughly 64% to 68%.

Series A: Give up another 20%. You own roughly 51% to 54%.

Series B: Give up another 15% to 20%. You own roughly 43% to 46%.

That math assumes clean rounds with no option pool refreshes and no SAFEs converting. In practice, option pool creation before each round (to attract talent) further dilutes founders before the investor calculation. By the time a typical venture-backed startup reaches Series B, the founding team collectively owns somewhere between 30% and 50%.

None of this is inherently bad - that's what the venture model is. But knowing it in advance helps you optimize each individual valuation conversation with the full picture in mind, rather than treating each round as an isolated negotiation.

What the Data Says About Negotiation Leverage

The most important valuation lever is not which method you use. It's how many investors are simultaneously interested in your deal.

Investor demand drives valuations up. Weak demand limits a startup's ability to raise at any price. Two competing term sheets beat any valuation model. Founders should never run a sequential fundraising process - pitching one investor, waiting for a decision, then moving to the next.

The parallel process is hard to manage logistically. But the valuation upside is significant. A founder with competing term sheets from two credible investors can often push valuation 20% to 40% above what a single-investor process would yield, simply because the investor knows there is an alternative.

If you can not generate competing interest organically, the Scorecard and comparable transaction methods serve as your best defense. They give you a data-driven anchor that any investor has to engage with rather than simply overriding with a take-it-or-leave-it offer.

The High-Resolution Fundraising Model

One approach gaining traction with founders who want to minimize dilution is what practitioners are calling high-resolution fundraising. Instead of setting a single SAFE cap or a single priced round, founders run staged closes - starting at a $6 million cap, then raising the cap to $8 million when the first tranche fills, then to $10 million for the final tranche.

This approach allows early believers to get rewarded with a lower cap while later investors - who are coming in with less risk - pay a higher effective price. It creates a built-in incentive for investors to commit early, and it allows the valuation to respond to real market demand rather than being set once based on projections.

The tradeoff is complexity. Running a staged close requires careful legal documentation and investor communication to avoid confusion about who owns what at each step. But for founders who have strong initial interest and expect that interest to grow, it can meaningfully reduce total dilution versus a single large round at a single fixed cap.

Validation Signals in Formal Methods

Every formal valuation method focuses on factors that are internal to the startup - team, product, market, traction. What they underweight is the signal that comes from who else has validated your company.

A YC acceptance does not show up as a line item in the Berkus Method. A signed LOI from a Fortune 500 potential customer is treated the same as zero LOIs in most Scorecard implementations. A recognizable lead investor from a prior company does not have a dedicated category in the Risk Factor Summation Method.

These signals move valuations. YC graduates at demo day consistently raise at the top of or above their stage's normal range. A warm introduction from a respected VC to another VC carries implicit validation that lifts the conversation before any numbers are mentioned.

The practical lesson: formal methods give you a floor. Accelerator programs move you up. A recognizable lead investor name moves you up. Enterprise customer logos move you up. Building that validation stack before the raise is often more valuable than perfecting your financial model.

Common Valuation Mistakes and What They Cost You

Every mistake in the valuation conversation has a specific equity cost. Here are the ones that show up most often and what they do to your cap table.

Using the wrong comparable set. A SaaS founder benchmarking against fintech comps will set a valuation that sophisticated investors immediately identify as wrong. It damages credibility before the conversation about your business even starts. Always match your comparables by industry, stage, and geography.

Anchoring on the ZIRP peak. Founders who raised in the peak period often have founders or advisors who still reference those numbers as the baseline. Current market valuations are 25% to 33% below those peaks at the pre-seed and seed stages. Walking in with peak-era anchor numbers immediately positions you as out of touch with market conditions.

Ignoring dilution from option pool creation. I see this on nearly every term sheet - the option pool gets created before the investment closes. That pool comes out of pre-money valuation, which means it dilutes the founders, not the new investor. A $6 million pre-money valuation with a 15% option pool creation required is functionally closer to a $5.1 million effective pre-money valuation for founders.

Setting a valuation without a runway model. Valuation and round size are connected. If you set a valuation that requires you to raise too little for 18 months of runway, you will be back in the market in 12 months - usually at a worse position. Build the round size around the runway you need first, then work backward to the ownership stake you're offering.

Treating valuation as the only term that matters. Liquidation preferences, pro-rata rights, anti-dilution provisions, and information rights all affect what founders actually receive at exit. A $12 million valuation with a 2x liquidation preference and full ratchet anti-dilution can be a worse deal than a $9 million valuation with clean standard terms.

What a Strong Valuation Conversation Looks Like in Practice

When you walk into a pitch with a defensible valuation, the conversation goes differently. Here is what strong preparation looks like in practice.

You have three to five recent comparable transactions in your geography and industry with the implied multiples calculated. You have run the Scorecard Method against those comparables and can show how your adjusted score compares. You know the regional benchmark for pre-seed valuations in your market. You have modeled dilution across three rounds to show that the economics still work for you at the proposed valuation.

You can explain the VC Method math from the investor's perspective - what terminal value your company would need to reach to justify their required return, and why that terminal value is realistic given market size and growth rates in your industry.

And critically, you have more than one investor in the pipeline. The formal methods are your anchor. Competing investor interest is your advantage. Both together are what get you to the top of your range.

One operator who has run multiple funded businesses described the dynamic this way. The numbers in the pitch are almost never the numbers in the term sheet. The formal valuation methods create a starting point. Getting both sides of that equation right is the actual work.

Final Take - The Method Matters Less Than the Moment

Every method in this guide is a tool, not a truth. The Berkus Method will not tell you what your startup is worth. Neither will DCF or comparable transactions. What they do is give you a defensible starting point for a conversation that is ultimately driven by investor conviction, market conditions, and competitive dynamics among investors.

The founders who consistently raise at strong valuations are not the ones who built the most sophisticated model. They understood the current market benchmarks. They picked the right comparables and created genuine investor competition. Walking in with validation signals that went beyond the spreadsheet is what separated them.

Use the methods to set a defensible range. Know your regional and industry benchmarks so you can counter pushback with data. Model dilution across rounds so you are not optimizing one round at the expense of your long-term cap table. And when it comes to the valuation number itself - Musk had it right. A lower number from the right partner beats a higher number from the wrong one every time.

FAQs